Results 71 to 80 of about 38,738 (212)

Incretin-based therapy for the treatment of bone fragility in diabetes mellitus [PDF]

, 2018
Bone fractures are common comorbidities of type 2 diabetes mellitus (T2DM). Bone fracture incidence seems to develop due to increased risk of falls, poor bone quality and/or anti-diabetic medications.
B. Bouvard, B. Gobron, D. Chappard, G. Mabilleau   +3 more
core   +2 more sources

Intra-islet GLP-1, but not CCK, is necessary for β-cell function in mouse and human islets [PDF]

, 2020
Glucagon-like peptide 1 (GLP-1) and cholecystokinin (CCK) are gut-derived peptide hormones known to play important roles in the regulation of gastrointestinal motility and secretion, appetite, and food intake.
Davis, Dawn, de Souza, Arnaldo Henrique, Kibbe, Carly R., Linnemann, Amelia K., Merrins, Matthew J., Saghafi, Samuel T., Tang, Jiayin, Yadev, Amanjot Kaur   +7 more
core   +1 more source

A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. [PDF]

, 2014
It is well known that the ω-3 fatty acids (ω-3-FAs; also known as n-3 fatty acids) can exert potent anti-inflammatory effects. Commonly consumed as fish products, dietary supplements and pharmaceuticals, ω-3-FAs have a number of health benefits ascribed ...
Akiyama, Taro E, Armando, Aaron M, Bogner-Strauss, Juliane G, Chi, Tyler J, Chung, Heekyung, Cox, Jason M, Di Salvo, Jerry, Evans, Ronald M, Hah, Nasun, Lackey, Denise, Lagakos, William S, McNelis, Joanne, Oh, Da Young, Olefsky, Jerrold M, Pessentheiner, Ariane R, Powels, Mary Ann, Quehenberger, Oswald, Sasik, Roman, Sinz, Christopher, Walenta, Evelyn, Watkins, Steven M   +20 more
core   +1 more source

Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes [PDF]

, 2016
Theglucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secretedfromthreemajor tissues inhumans,enteroendocrine L cells in the distal intestine, a cells in the ...
Adelhorst, Alastair J. H. Brown, Andersen, Avatapalle, Belin, Brown, Caihong Zhou, Chris de Graaf, Dan Donnelly, Davis, Dehua Yang, Denise Wootten, Denker, Dods, Drucker, Elahi, Ferguson, Gallwitz, Goodman, Green, Grynkiewicz, Gustavson, Göke, Hendrick, Heppner, Hjorth, Holst, Holst, Huang, Jendle, Jesper Lau, Jiayu Liao, Jiejie Deng, Jung-Mo Ahn, La Barre, Laurence J. Miller, Li, Locatelli-Hoops, Lund, Madeleine M. Fletcher, Ming-Wei Wang, Mojsov, Mojsov, Nauck, Nauck, Orskov, Orskov, Patrick M. Sexton, Pocai, Prentki, Rhodes, RICHARD DEQUAN YE, Sancho, Shiue, Steensgaard, Tang-Christensen, Tibaduiza, Tomkin, Unson, Wettergren, Widmann, Wild, Willard, Zunz   +63 more
core   +3 more sources

GLP-1 Receptor Agonist

The Journal of Korean Diabetes
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by food intake from L cells of the ileum. GLP-1 contributes to blood glucose control through three main mechanisms: promoting glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon hypersecretion from pancreatic alpha cells, and delaying gastric emptying time.
openaire   +1 more source

The extrapancreatic effects of glucagon-like peptide-1 and related peptides [PDF]

, 2009
Context: Glucagon-like peptide-1 (GLP-1) 7-36 amide, an insulinotropic hormone released from the intestinal L cells in response to nutrient ingestion, has been extensively reviewed with respect to -cell function.
Abu Hamdah, Rania, Rabiee, Atoosa, Meneilly, Graydon S., Shannon, Richard P., Andersen, Dana K., Elahi, Dariush   +5 more
core   +1 more source

Microbiota-Produced N-Formyl Peptide fMLF Promotes Obesity-Induced Glucose Intolerance. [PDF]

, 2019
The composition of the gastrointestinal microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose ...
Chan, Luisa S, Chordia, Mahendra D, El Ouarrat, Dalila, Han, Andrew W, Jain, Mohit, Johnson, Andrew MF, Lee, Yun Sok, Mahmood, Nadir A, Ofrecio, Jachelle M, Olefsky, Jerrold M, Pan, Dongfeng, Riopel, Matthew, Ryan, Caitlin N, Watrous, Jeramie D, Wollam, Joshua, Xu, Yong-Jiang, Ying, Wei   +16 more
core   +1 more source

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): a short‐term cost‐effectiveness analysis in the UK setting [PDF]

, 2018
Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
ADVANCE Collaborative Group, American Diabetes Association Consensus Panel, Anderson, Bagust, Bagust, Billings, Blak, Boye, Chubb, Control Group, Currie, Donnelly, Duckworth, Evans, Forst, Gaede, Gaede, Giugliano, Grandy, Hammer, Holman, Hunt, Hunt, Hunt, Inzucchi, Ismail-Beigi, Johnston, Lee, Matza, McCabe, Meneghini, Mezquita-Raya, National Institute for Health and Care Excellence (NICE), Nauck, Parekh, Peyrot, Peyrot, Ridderstråle, Russell-Jones, Shi, Stettler, The Forum for Injection Technique (FIT), TREND-UK, UK Prospective Diabetes Study (UKPDS) Group, UK Prospective Diabetes Study (UKPDS) Group, Walz, Wang, Wild   +47 more
core   +1 more source

Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study

The Lancet. Healthy Longevity
Summary: Background: GLP-1 receptor agonists and SGLT2 inhibitors are increasingly being used in people with type 2 diabetes on the basis of findings from randomised clinical trials; however, little is known of whether clinical outcomes are affected by ...
ProfPhD Fei-Yuan Hsiao, Elise Chia-Hui Tan, PhD, Lin-Chieh Meng, MS, Yi-Chin Lin, PharmD MS, Ho-Min Chen, MS, Shang-Ting Guan, PharmD, ProfMD PhD Der-Cherng Tarng, PharmD, ProfMD PhD Chih-Yuan Wang, PharmD, Prof Liang-Kung Chen, PharmD   +8 more
doaj   +1 more source

Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]

, 2010
Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Shyangdan, D. (Deepson), Royle, Pamela, Clar, C., Sharma, Pawana, Waugh, Norman   +4 more
core   +4 more sources